Real-world study of atezolizumab plus bevacizumab for liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how well the combination of atezolizumab and bevacizumab works for people with liver cancer that has come back or spread, based on real patient records from a hospital registry.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with liver cancer (HCC) that cannot be surgically removed because it has come back or spread
- You have received at least one cycle of atezolizumab plus bevacizumab
- You have had an upper endoscopy (EGD) before starting treatment
- You have not had any other cancer treatment by mouth or vein (systemic therapy) for your liver cancer
- You have not had any other cancer diagnosis before this one
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer that cannot be removed by surgery. Researchers will study blood samples to find markers that might predict how well the treatment works.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This study tests a first-line immunotherapy combination (like atezolizumab + bevacizumab or similar drugs) for advanced liver cancer that can't be removed. It aims to see how well these treatments work and how safe they are in real-world patients.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This trial studies how well atezolizumab and bevacizumab work together with radiation to treat advanced hepatocellular carcinoma (liver cancer) that has spread into the portal vein. It may help shrink or control tumors and improve outcomes, but you must meet several safety and cancer-location criteria.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.